巴氯芬
肌肉松弛剂
痉挛
药理学
γ-氨基丁酸受体
兴奋剂
上瘾
神经科学
医学
食品药品监督管理局
心理学
麻醉
受体
内科学
作者
Caitlin N. Kent,Charlotte Park,Craig W. Lindsley
标识
DOI:10.1021/acschemneuro.0c00254
摘要
Baclofen, β-(4-chlorophenyl)-γ-aminobutyric acid, holds a unique position in neuroscience, remaining the only U.S. Food and Drug Administration (FDA) approved GABAB agonist. While intended to be a more brain penetrant, i.e, ability to cross the blood-brain barrier (BBB), version of GABA (γ-aminobutyric acid) for the potential treatment of epilepsy, baclofen's highly efficacious muscle relaxant properties led to its approval, as a racemate, for the treatment of spasticity. Interestingly, baclofen received FDA approval before its receptor, GABAB, was discovered and its exact mechanism of action was known. In recent times, baclofen has a myriad of off-label uses, with the treatment for alcohol abuse and drug addiction garnering a great deal of attention. This Review aims to capture the >60 year legacy of baclofen by walking through the history, pharmacology, synthesis, drug metabolism, routes of administration, and societal impact of this Classic in chemical neuroscience.
科研通智能强力驱动
Strongly Powered by AbleSci AI